Prof. Gregor Serša, Dsci (Biol.)

• Prof. Gregor Serša, Dsci (Biol.)
• Titles and functions
• Education
• Work Experiences
• Memberships in National and International Associations
• Prizes and Awards
• Major publications

• Assistant Medical Director for Research and Education
• Full Professor

Professor Serša is researcher; he has been involved in translational research in oncology at the Institute of Oncology Ljubljana for 25 years. In his position of the principal investigator of the research program, he is in charge of experimental oncology investigations and is particularly focused to biomedical application of electroporation.

His main fields of interest are electroporation in targeted delivery of cytostatics into tumors (the researches have already reached the clinical phase), and recently, electrogene therapy (a research field that has great prospects to be translated into clinical practice).

Besides experimental work, he is actively involved in the education of undergraduate and postgraduate students. He is mentor to research fellows at the Institute of Oncology, lecturer at the University College of Health Studies (undergraduate level) and in postgraduate studies of biomedicine and biotechnics at the University of Ljubljana. He was appointed National Coordinator for Oncology; in this capacity, he coordinates medical researches in oncology.

• From 1982 onwards: Slovenian Immunological Society
• From 1986 onwards: Slovenian Biophysical Society
• From 1989 onwards: Slovenian Society of Medical and Biological Engineering
• From 1996 onwards: AACR American Association for Cancer Research
• From 1997 onwards: ESTRO, The European Society for Therapeutic Radiology and Oncology
• From 2006: BACR The British Association for Cancer Research

• 1979: Preseren Award for Students
• 1995: Award of the Republic of Slovenia for Scientific and Research Achievements (shared with Prof. Lojze Vodovnik and Prof. Damijan Miklavčič)

• SERŠA G, Willingham V, Milas L. Antitumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer 1988; 42: 129–34.
• SERŠA G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450–5.
• Miklavčič D, Beravs K, Šemrov D, Čemažar M, Demšar F, SERŠA G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998; 74: 2152–8.
• Mir LM, Glass LF, SERŠA G, Teissie J, Domenge C, Miklavčič D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek JJr, Bachaud JM, DeConti R, Štabuc B, Čemažar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Brit J Cancer 1998; 77: 2336–42.
• SERŠA G, Kranjc S, Čemažar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 2000; 46: 1037–41.
• SERŠA G, Štabuc B, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863–7.
• SERŠA G, Kržič M, Šentjurc M, Ivanuša T, Beravs K, Čemazar M, Auersperg M, Swartz HM. Reduced tumor oxygenation by treatment with vinblastine. Cancer Res 2001; 61: 4266–71.
• Čemažar M, SERŠA G, Wilson J, Tozer GM, Hart SL, Grošel A, Dachs G. Effective gene transfer to solid tumours using different non-viral gene delivery techniques: electroporation, liposomes and integrin-targeted vector. Cancer Gene Ther 2002; 9: 399–406.
• Čemažar M, Grošel A, Glavač D, Kotnik V, Skoberne M, Kranjc S, Mir LM, Andre F, Opolon P, SERŠA G. Effects of electrogenetherapy with p53wt combined with cisplatin on survival of human tumor cell lines with different p53 status. DNA Cell Biol 2003; 22: 765–75.
• Reberšek M, Čufer T, Čemažar M, Kranjc S, SERŠA G. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs 2004; 15: 593–7.
• Snoj M, Rudolf Z, Čemažar M, Jančar B, SERŠA G. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anti-Cancer Drugs 2005; 16: 345-8.
• Tozon N, Kodre V, SERŠA G, Čemažar M. Effective treatment of perianal tumours in dogs with electrochemotherapy. Anticancer Research 2005; 25: 839-46.
• Kranjc S, Čemažar M, Grošel A, Šentjurc M, SERŠA G. Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer 2005; 5: 115.
• SERŠA G. Čemažar M. Miklavčič D., Rudolf Z. Elektrokemoterapija postaja standardno zdravljenje. Onkologija 2005, IX: 84-7.
• Čemažar M, Golzio M, Rols MP, SERŠA G, Teissie J. Electrically-assisted nucleic acid delivery in vivo: Where do we stand? Review. Current Pharmaceutical Design 2006; 12: 3817-25.
• Čemažar M, Pavlin D, Kranjc S, Grošel A, Mesojednik S, SERŠA G. Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Current Drug Delivery 2006, 3: 77-81
• Čemažar M, Golzio M, Escoffre JM, Couderc B, SERŠA G, Teissie J. In vivo imaging of tumour growth after electrochemotherapy with cisplatin. Biochem Biophys Res Commun 2006, 348: 997-1002.
• Grabner S, Čemažar M, Bukovec N, SERŠA G. syntheses and cytotoxicity of Pt(II) complexes with Acyclovir. Acta Chim Slov 2006; 51: 153-6.
• Pavlin D, Tozon N, Serša G, Pogačnik A, Čemažar M. Electrogene therapy in cancer treatment. Slov Vet Res 2006; 43: 77-84.
• SERŠA G, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy of tumours. Radiol Oncol 2006; 40(3): 163-74.
• Snoj M, Rudolf Z, Paulin-Košir S, Čemažar M, Snoj R, SERŠA G. Long lasting complete response in melanoma treated by electrochemotherapy. EJC Suppl 2006; 4: 26-8.
• SERŠA G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. EJC Suppl 2006; 4: 52-9.
• Mir L M, Gehl J, SERŠA G, Collins CG, Garbay JR, Billard V, Geertsen P, Rudolf Z, O’Sullivan GC, Marty M. Standard Operating Procedures of the Electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by Cliniporator ™ by means of invasive or non-invasive electrodes. EJC Suppl 2006; 4: 14-25.
• Marty M, SERŠA G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavčič D, Pavlović I, Paulin-Kosir SM, Čemažar M, Morsli N, Soden DM, Rudolf Z, Robert C, O’Sullivan GC, Mir LM. Electrochemotherapy – an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13.
• Grošel A, SERŠA G, Kranjc S, Čemažar M. Electrogene therapy with p53 of murine sarcomas alone or combined with electrochemotherapy using cisplatin. DNA Cell Biol 2006, in press.
• Kanthou C, Kranjc S, SERŠA G, Tozer GM, Zupanič A, Čemažar M. The endothelial cytoskeleton as a target of electroporation based therapies. M